Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Chris Braumann
Based on 7 articles published since 2010
(Why 7 articles?)
||||

Between 2010 and 2020, C. Braumann wrote the following 7 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Prognostic value and impact of cerebral metastases in pancreatic cancer. 2020

Luu, Andreas Minh / Künzli, Beat / Hoehn, Philipp / Munding, Johanna / Lukas, Carsten / Uhl, Waldemar / Braumann, Chris. ·Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. · Department of Pathology, University-Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany. · Department of Radiology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. ·Acta Chir Belg · Pubmed #30614389.

ABSTRACT:

2 Article Surprising Twist in the Plot - Sister Mary Joseph's Nodule of Pancreatic Cancer Mimicking Wound Infection after Umbilical Hernia Repair. 2019

Luu, Andreas M / Meurer, K / Herzog, T / Munding, J / Uhl, W / Braumann, C. ·Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791, Bochum, Germany. a.luu@klinikum-bochum.de. · Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791, Bochum, Germany. · Institute of Pathology, University-Hospital Bergmannsheil, Ruhr-University Bochum, Buerkle de la Camp Platz 1, 44789, Bochum, Germany. ·J Gastrointest Cancer · Pubmed #28589449.

ABSTRACT:

3 Article Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo. 2017

Buchholz, M / Majchrzak-Stiller, B / Hahn, S / Vangala, D / Pfirrmann, R W / Uhl, W / Braumann, C / Chromik, A M. ·Division of Molecular and Clinical Research, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. marie.buchholz-a7y@rub.de. · Division of Molecular and Clinical Research, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. · Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany. · Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany. · Geistlich Pharma AG, Wolhusen, Switzerland. ·BMC Cancer · Pubmed #28340556.

ABSTRACT: BACKGROUND: Former studies already revealed the anti-neoplastic properties of the anti-infective agent Taurolidine (TRD) against many tumor species in vitro and in vivo. Its anti-proliferative and cell death inducing capacity is largely due to its main derivative Taurultam (TRLT). In this study it could be demonstrated, that substance 2250 - a newly defined innovative structural analogue of TRLT - exhibits an anti-neoplastic effect on malignant pancreatic carcinoma in vitro and in vivo. METHODS: The anti-neoplastic potential of substance 2250 as well as its mode of action was demonstrated in extensive in vitro analysis, followed by successful and effective in vivo testings, using xenograft models derived from established pancreatic cancer cell lines as well as patient derived tissue. RESULTS: Our functional analysis regarding the role of oxidative stress (ROS) and caspase activated apoptosis showed, that ROS driven programmed cell death (PCD) is the major mechanisms induced by substance 2250 in pancreatic carcinoma. What is strongly relevant towards clinical practice is especially the observed inhibition of patient derived pancreatic cancer tumor growth in mice treated with this new substance in combination with its sharply higher metabolic stability. CONCLUSION: These encouraging results provide new therapeutical opportunities in pancreatic cancer treatment and build the basis for further functional analysis as well as first clinical studies for this promising agent.

4 Article Liver Metastases 10 Years after Resection of a "Benign" Insulinoma. 2016

Luu, Andreas Minh / Herzog, Torsten / Uhl, Waldemar / Braumann, Chris. ·Katholisches Klinikum Bochum-St. Josef Hospital Klinik für Allgemein- und Viszeralchirurgie Bochum, Germany. ·Am Surg · Pubmed #28206926.

ABSTRACT: -- No abstract --

5 Article [Distal Pancreatectomy with Autologous Fibrin Sealant - Implementation of an Established Concept of Tissue Sealing in Pancreatic Surgery]. 2016

Luu, A M / Braumann, C / Belyaev, O / Janot, M / Uhl, W / Herzog, T. ·Klinik für Allgemein- und Viszeralchirurgie, Katholisches Klinikum Bochum - St. Josef-Hospital, Deutschland. ·Zentralbl Chir · Pubmed #27501071.

ABSTRACT:

6 Unspecified Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. 2019

Luu, Andreas Minh / Hoehn, Philipp / Vogel, Sina Rabea / Reinacher-Schick, Anke / Munding, Johanna / Uhl, Waldemar / Braumann, Chris. ·Department of General and Visceral Surgery, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. · Department of Oncology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. · Institute of Pathology, University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany. ·Visc Med · Pubmed #31934588.

ABSTRACT: Introduction: Pancreatic cancer is a lethal disease and often asymptomatic. Therefore, it is most often diagnosed at an advanced stage. The standard approach in a metastasized tumor stage is palliative chemotherapy. However, the prognosis remains extremely poor. Case Report: We present the case of a patient who was diagnosed with a cancer of the head of the pancreas with hepatic metastases. After receiving palliative intended chemotherapy with the FOLFIRINOX regimen, staging computed tomography revealed the disappearance of the liver metastases and local resectability of the pancreatic head tumor. The patient underwent an uneventful Whipple's procedure. Surprisingly, pathohistological investigation revealed a complete pathological response. Conclusion: Pathological complete response after FOLFIRINOX treatment in hepatic metastasized pancreatic cancer is extremely rare. It enables surgical resection and increases the survival rate significantly.

7 Unspecified FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. 2018

Luu, Andreas Minh / Herzog, Torsten / Hoehn, Philipp / Reinacher-Schick, Anke / Munding, Johanna / Uhl, Waldemar / Braumann, Chris. ·Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. · Department of Oncology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. · Institute of Pathology, University-Hospital Bergmannsheil, Bochum, Germany. ·J Gastrointest Oncol · Pubmed #29755782.

ABSTRACT: Pancreatic cancer (PC) is a lethal disease with a poor prognosis. It is typically asymptomatic and therefore most often diagnosed at an advanced stage. A primary unresectable PC can become resectable in case of tumor regression turning palliative into neoadjuvant therapy. We present a 67-year old female patient who was diagnosed with a locally advanced adenocarcinoma of the pancreatic head. After receiving palliative intended chemotherapy with the FOLFIRINOX regimen, staging computed tomography revealed local resectability of the pancreatic head tumor. The patient underwent an uneventful total pancreatectomy. Pathohistological investigation revealed a pathologic complete response (pCR). pCR after FOLFIRINOX treatment in primary unresectable PC is extremely rare. It might enable surgical resection and can increase the survival rate.